However, in contrast to a KRAS-only mutation and a KRAS co-mutation with TP53, the SMARCA4-mutated KRAS-driven lung adenocarcinomas display poorer clinical outcome with a shorter overall survival and disease-free survival. The gene discussed is KRAS; the disease is lung adenocarcinoma.